Automate Your Wheel Strategy on DVA
With Tiblio's Option Bot, you can configure your own wheel strategy including DVA - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol DVA
- Rev/Share 158.4561
- Book/Share 13.4546
- PB -20.0055
- Debt/Equity -23.1154
- CurrentRatio 1.2917
- ROIC 0.107
- MktCap 10112916720.0
- FreeCF/Share 15.2223
- PFCF 7.716
- PE 17.4413
- Debt/Assets 0.861
- DivYield 0
- ROE -1.6063
- Rating B-
- Score 3
- Recommendation Neutral
- P/E Score 3
- DCF Score 5
- P/B Score 1
- D/E Score 1
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| No ratings available. | |||||||
News
DaVita Inc. to Participate in TD Cowen's 46th Annual Health Care Conference
Published: February 24, 2026 by: PRNewsWire
Sentiment: Neutral
DENVER, Feb. 24, 2026 /PRNewswire/ -- DaVita Inc. (NYSE: DVA) today announced that its chief financial officer, Joel Ackerman, and its group vice president of investor relations, Nic Eliason, will participate in a fireside chat with investors at TD Cowen's 46th Annual Health Care Conference on Monday, March 2, 2026 at 11:50 am EST. To view the live webcast, visit the TD Cowen page here and create a free registration.
Read More
Here's Why DaVita HealthCare (DVA) is a Strong Value Stock
Published: February 24, 2026 by: Zacks Investment Research
Sentiment: Positive
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Read More
Why DaVita HealthCare (DVA) is a Top Momentum Stock for the Long-Term
Published: February 20, 2026 by: Zacks Investment Research
Sentiment: Positive
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Read More
5 Value Stocks to Buy Now as Fed Debates Next Rate Move
Published: February 19, 2026 by: Zacks Investment Research
Sentiment: Neutral
DVA, F, CGAU, LUV and PAX emerge as top high earnings yield stocks amid Fed rate uncertainty.
Read More
4 Discounted PEG Value Stocks to Boost Your Portfolio's Health
Published: February 10, 2026 by: Zacks Investment Research
Sentiment: Positive
Discounted PEG screen highlights four value stocks, led by healthcare. One can pick Exelixis, alongside DaVita, Phibro and Allison Transmission.
Read More
Why DaVita HealthCare (DVA) is a Top Value Stock for the Long-Term
Published: February 05, 2026 by: Zacks Investment Research
Sentiment: Positive
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Read More
Should Value Investors Buy DaVita (DVA) Stock?
Published: February 05, 2026 by: Zacks Investment Research
Sentiment: Positive
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Read More
3 Warren Buffett-Style Stocks for a Golden Retirement
Published: February 04, 2026 by: 24/7 Wall Street
Sentiment: Neutral
Although former Berkshire Hathaway (NYSE:BRK-B) CEO Warren Buffett retired as the company's chief executive, his legacy looms large.
Read More
DaVita Stock Up Following Q4 Earnings & Revenue Beat, Margins Expand
Published: February 03, 2026 by: Zacks Investment Research
Sentiment: Positive
DVA reports a fourth-quarter 2025 earnings and revenue beat as margins expanded and full-year adjusted EPS rose by double digits.
Read More
TER Quarterly Sales Top $1B, DVA & PEP Beat Earnings
Published: February 03, 2026 by: Schwab Network
Sentiment: Positive
The AI trade is helping Teradyne (TER), with Diane King Hall pointing to the company's latest earnings as a signal of forward strength. Outside of tech, she notes DaVita's (DVA) earnings beat and guidance above expectations as it recovers from a malware attack.
Read More
DaVita: Some Success Is Possible, But Volatility Is Still Heavy
Published: February 03, 2026 by: Seeking Alpha
Sentiment: Positive
DaVita (DVA) delivered a strong earnings beat, driving a 13.5%+ share price surge and reinforcing my positive outlook. DVA's strategy leverages home dialysis, integrated kidney care, and international expansion, supporting double-digit growth and margin stability despite sector headwinds. I maintain a fair value of $185/share and a price target of $130/share, reiterating a 'BUY' rating even after the recent upswing.
Read More
DaVita Inc. (DVA) Q4 2025 Earnings Call Transcript
Published: February 02, 2026 by: Seeking Alpha
Sentiment: Neutral
DaVita Inc. (DVA) Q4 2025 Earnings Call Transcript
Read More
DaVita HealthCare (DVA) Q4 Earnings and Revenues Surpass Estimates
Published: February 02, 2026 by: Zacks Investment Research
Sentiment: Positive
DaVita HealthCare (DVA) came out with quarterly earnings of $3.4 per share, beating the Zacks Consensus Estimate of $3.24 per share. This compares to earnings of $2.24 per share a year ago.
Read More
DaVita forecasts 2026 profit above estimates on steady dialysis service demand; shares jump
Published: February 02, 2026 by: Reuters
Sentiment: Positive
DaVita projected annual profit above estimates on Monday after reporting better-than-expected fourth-quarter results on steady demand for its kidney dialysis services, sending its shares up 13% in after-hours trading.
Read More
DaVita Inc. 4th Quarter 2025 Results
Published: February 02, 2026 by: PRNewsWire
Sentiment: Neutral
DENVER, Feb. 2, 2026 /PRNewswire/ -- DaVita Inc. (NYSE: DVA) announced financial and operating results for the quarter and year ended December 31, 2025. "Our strong platform delivered once again in 2025, providing high quality, innovative care to our patients and achieving the financial targets we set out at the beginning of the year despite a challenging environment," said Javier Rodriguez, CEO of DaVita.
Read More
Can Operational Execution Support DaVita's Q4 Performance?
Published: January 30, 2026 by: Zacks Investment Research
Sentiment: Positive
DVA's fourth-quarter 2025 performance is likely to have gained from technology upgrades, cost control and seasonal boosts despite ongoing volume headwinds.
Read More
Here's Why You Should Hold DaVita Stock in Your Portfolio for Now
Published: January 19, 2026 by: Zacks Investment Research
Sentiment: Positive
DVA stock benefits from a patient-centric model, third-quarter revenue growth and overseas expansion, though reliance on commercial payers remains a risk.
Read More
4 Outpatient Home Health Stocks in Focus as Market Dynamics Change
Published: December 19, 2025 by: Zacks Investment Research
Sentiment: Positive
An aging population and rising AI adoption position the Zacks Medical - Outpatient and Home Healthcare industry for solid growth. EHC, DVA, OPCH and PNTG stand to benefit.
Read More
Here's Why You Should Hold DaVita Stock in Your Portfolio for Now
Published: December 18, 2025 by: Zacks Investment Research
Sentiment: Positive
DVA stock gets support from a patient-centric model, Q3 revenue growth and overseas expansion, even as reliance on commercial payers remains a risk.
Read More
DaVita: More Volatile But Better Upside Than Fresenius
Published: December 03, 2025 by: Seeking Alpha
Sentiment: Negative
DaVita (DVA) is rated a speculative 'Buy,' reflecting undervaluation despite recent earnings volatility. DVA's moat stems from its dominant US dialysis clinic network, but its reliance on Medicare reimbursement and lack of dividend heighten risk. Trading below 11.5x P/E, DVA offers potential double-digit annual returns if it reverts to historical valuation multiples.
Read More
Why Is DaVita HealthCare (DVA) Up 1.1% Since Last Earnings Report?
Published: November 28, 2025 by: Zacks Investment Research
Sentiment: Positive
DaVita HealthCare (DVA) reported earnings 30 days ago. What's next for the stock?
Read More
DaVita Inc. (DVA) Presents at 7th Annual Wolfe Research Healthcare Conference Transcript
Published: November 17, 2025 by: Seeking Alpha
Sentiment: Neutral
DaVita Inc. ( DVA ) 7th Annual Wolfe Research Healthcare Conference November 17, 2025 11:20 AM EST Company Participants Joel Ackerman - CFO & Treasurer Conference Call Participants Justin Lake - Wolfe Research, LLC Presentation Justin Lake Wolfe Research, LLC All right. Good morning.
Read More
DaVita Stock Down Post Q3 Earnings Miss Estimates, Revenues Up Y/Y
Published: October 30, 2025 by: Zacks Investment Research
Sentiment: Negative
DVA's Q3 earnings miss estimates despite revenue growth, as margins tightened and shares slipped post-results.
Read More
Can Technology and Cost Discipline Lift DaVita's Q3 Earnings?
Published: October 28, 2025 by: Zacks Investment Research
Sentiment: Positive
DVA's third-quarter 2025 performance is likely to benefit from technology upgrades and cost control while battling high missed treatments and low volume growth.
Read More
3 Healthcare Stocks That Are Screaming Deals Right Now
Published: October 26, 2025 by: The Motley Fool
Sentiment: Positive
DaVita's recession-resistant business is growing internationally, but shares continue to trade at a heavily discounted valuation. Merck could be in for a major move if the pharma can soften the blow of an upcoming patent expiration.
Read More
DaVita HealthCare (DVA) is a Top-Ranked Growth Stock: Should You Buy?
Published: October 03, 2025 by: Zacks Investment Research
Sentiment: Positive
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Read More
4 Outpatient Home Health Stocks Worth Watching Amid Shifting Trends
Published: September 24, 2025 by: Zacks Investment Research
Sentiment: Positive
An aging global population and AI dominance are likely to drive the Zacks Medical - Outpatient and Home Healthcare industry despite the macroeconomic challenges. DGX, DVA, ADUS and PNTG are well-poised to gain.
Read More
Why DaVita HealthCare (DVA) is a Top Growth Stock for the Long-Term
Published: September 17, 2025 by: Zacks Investment Research
Sentiment: Positive
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Read More
DaVita Honors 25 Years of Clinical Advancement in Chronic Disease Care
Published: August 27, 2025 by: PRNewsWire
Sentiment: Neutral
Largest kidney care research arm advances science to inform care delivery DENVER , Aug. 27, 2025 /PRNewswire/ -- As part of its 25th-anniversary celebration, DaVita, a leading provider of comprehensive kidney care, is proud to spotlight the groundbreaking work of its wholly owned research arm, DaVita Clinical Research (DCR). For a quarter-century, DCR has played a pivotal role in advancing kidney care — driving access to new therapies, improving clinical outcomes and shaping the future of nephrology through rigorous research and clinical trials.
Read More
Ransomware attack at dialysis firm DaVita affects 2.7 million people, US health dept website shows
Published: August 21, 2025 by: Reuters
Sentiment: Negative
A ransomware attack that encrypted certain elements of dialysis firm DaVita's network affected 2.7 million people, the U.S. health department's website showed on Thursday.
Read More
About DaVita Inc. (DVA)
- IPO Date 1995-10-31
- Website https://www.davita.com
- Industry Medical - Care Facilities
- CEO Javier J. Rodriguez
- Employees 76000